Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PET scan imaging in oncology.

G Jerusalem1, R Hustinx, Y Beguin

  • 1Department of Medicine, Division of Medical Oncology and Hematology, CHU Sart Tilman, B35, B-4000-Liege 1, Belgium. g.jerusalem@chu.ulg.ac.be

European Journal of Cancer (Oxford, England : 1990)
|July 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.

European journal of nuclear medicine and molecular imaging·2026
Same author

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Breast cancer research : BCR·2023
Same author

Radiotherapy modification based on artificial intelligence and radiomics applied to (<sup>18</sup>F)-fluorodeoxyglucose positron emission tomography/computed tomography.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

ESMO open·2023
Same author

[CAR-T cells therapy in solid tumors : where are we now ?]

Revue medicale de Liege·2022
Same author

Recurrent or primary metastatic cervical cancer: current and future treatments.

ESMO open·2022
Same journal

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Positron emission tomography (PET) shows high accuracy in detecting and staging cancers, and monitoring treatment. Further research is needed to confirm its impact on patient outcomes and cost-effectiveness for routine oncology use.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Positron emission tomography (PET) is transitioning from research to clinical practice.
  • Defining the optimal role of PET in oncology is crucial.

Purpose of the Study:

  • To review the potential applications of PET in oncology.
  • To discuss promising indications, future perspectives, and limitations of PET in cancer care.

Main Methods:

  • Review of existing literature on 18F-FDG PET in oncology.
  • Analysis of diagnostic accuracy, staging capabilities, and therapy monitoring effectiveness.

Main Results:

  • 18F-FDG PET demonstrates high accuracy in detecting and staging malignant tumors.

Related Experiment Videos

  • PET is effective in monitoring therapeutic response in cancer patients.

    • Conclusions:

    • PET holds significant potential in oncology, with established accuracy for tumor detection and staging.
    • Further evaluation of PET's impact on patient outcomes and cost-effectiveness is essential for its widespread clinical adoption.